Business Wire

GN Hearing Launches the Most Intuitive and Personalized Hearing Solution That Adapts to the User’s Daily Life

Jaa

GN Hearing now launches the world’s first hearing solutions that intuitively adapt to the hearing aid user’s personal preferences in any given sound environment. This innovative breakthrough technology employs GN’s artificial intelligence (AI) solution in tandem with Apple's Siri virtual assistant. The announcement was made at the Consumer Electronics Show (CES) 2019 in Las Vegas, the world’s largest and most influential technology event.

Yet another industry first from GN, it follows the company’s long-standing commitment to progressing hearing aid technologies through extensive research and development programs. This new offering follows years of investment in GN’s dedicated inhouse AI research center, investments in AudEERING and extensive collaboration with other partners and academic research institutes. The launch extends GN’s innovation footprint and partnership philosophy in the hearing care industry by offering the most intuitive and personalized hearing solution.

“At GN, we believe that technology is at its best when it helps address people’s everyday needs and challenges. Employing AI technology in GN’s products brings this specific technology and innovation to the hearing aid space and is the first step in the journey to create a seamless hearing experience that will allow hearing aid users to ‘forget’ that they are wearing one. This is core to GN’s purpose of making life sound better,” says Marcus Desimoni, CFO of GN and Interim CEO of GN Hearing.

The new, life-enhancing offering is an added benefit to the company’s latest and innovative 2.4 GHz product portfolio from ReSound and Beltone, and it will be reaching users in February 2019. Through our use of AI, we expect to deliver a continuous stream of new user benefits through future software releases. This will enable our users to always be at the forefront of innovation by updating existing GN Hearing instruments with new features.

When GN was established 150 years ago, the company introduced the world’s first telegraph line from Europe to Asia, creating the internet of its time. It is this same pioneering spirit that is being applied today to transform lives, helping people hear more, do more and be more than they ever thought possible.

- ENDS -

For further information, please visit our website: resound.com/ai

NOTES TO EDITORS

About GN

The GN Group is a global leader in intelligent audio solutions that let you hear more, do more and be more than you ever thought possible. Our ambitious 150-year journey has taken us from telegraph cables to radio waves and intelligent audio engineering. To celebrate our anniversary, we look to our unique competences within medical, professional and consumer audio solutions to help us continue to transform lives through the power of sound.

GN was founded with a truly innovative and global mindset. Today, we honor that legacy with world-leading expertise in the human ear, sound, wireless technology, miniaturization and collaborations with leading technology partners. GN's solutions are marketed by the brands ReSound, Beltone, Interton, Jabra and BlueParrott in 100 countries. Founded in 1869, the GN Group employs more than 6,000 people and is listed on Nasdaq Copenhagen (GN.CO).

Visit our homepage GN.com - and connect with us on LinkedIn, Facebook and Twitter.

ReSound is a trademark of GN Hearing A/S. Beltone is a trademark of GN Hearing Care Corporation. Apple, the Apple logo, iPhone, iPad and iPod touch and Siri are trademarks of Apple Inc., registered in the U.S. and other countries.

Contact information

Investors and analysts
Peter Justesen
Vice President, Investor Relations & Treasury
Email: pjustesen@gn.com
Tel: +45 45 75 87 16

Rune Sandager
Senior Investor Relations Manager
Email: rsandager@gn.com
Tel: +45 45 75 92 57

Press and the media
Lars Otto Andersen-Lange
Head of External Relations & Global Public Affairs
Email: loalange@gn.com
Tel: +45 45 75 02 55

Marie Schleimann Nordlund
Head of PR, Media & Communication
Email: mschleimannnordlund@gnhearing.com
Tel: +45 31 26 37 34

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Vertex Announces European Commission Approval for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease21.1.2019 12:00Tiedote

Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label extension for ORKAMBI® (lumacaftor/ivacaftor) for the treatment of children with cystic fibrosis (CF) aged 2 to 5 years old who have two copies of the F508del mutation, the most common form of the disease. “Today’s approval by the European Commission brings us one step closer to our goal of bringing treatment to all people living with CF,” said Reshma Kewalramani, MD, Executive Vice President, Global Medicines Development and Medical Affairs and Chief Medical Officer at Vertex. ‘‘By treating the underlying cause of disease early, we can potentially modify its course and offer patients the chance of improved outcomes.’’ The label update is based on data from a Phase 3 open-label safety study in 60 patients that showed treatment with lumacaftor/ivacaftor was generally well tolerated for 24 weeks, with a safety profile in these pediatric patients generally consistent with

Anticipation Builds as MWC19 Barcelona Approaches21.1.2019 12:00Tiedote

The GSMA today announced final updates for MWC19 Barcelona (formerly Mobile World Congress), including additional keynote speakers, participating companies, programmes and events. Taking place 25-28 February 2019, with events being staged at Fira Gran Via, Fira Montjuïc and La Farga L’Hospitalet, MWC19 Barcelona is set to attract more than 107,000 professionals from over 200 countries and territories. “With the anticipated arrival of 5G, this year’s event is set to be one of the most exciting as the industry convenes to showcase Intelligent Connectivity across new technologies on the brink of reaching millions of people across the world,” said John Hoffman, CEO, GSMA Ltd. “Over the four days of MWC19, attendees will have the opportunity to hear from leaders who are driving innovation and we look forward once again to welcoming the mobile world to Barcelona.” Global Leaders to Keynote The GSMA announced the addition of several new keynote speakers for MWC19 including executives from lea

B2C2 Launches Streaming OTC Pricing with Point-and-Click Execution21.1.2019 12:00Tiedote

B2C2, one of the largest cryptocurrency liquidity providers and the leader in electronic OTC trading, today announced the launch of streaming pricing with point-and-click execution on its OTC platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190121005063/en/ Max Boonen, Founder and CEO of B2C2 (Photo: Business Wire) For the first time, B2C2’s clients will be able to view and execute trades on a real-time two-way market, via the firm’s secure web interface. The new functionality allows market participants to easily monitor live pricing in user-defined quantities and execute with the click of a button, as they would on traditional FX trading platforms. The launch rounds out a number of milestones for B2C2 in 2018, including surpassing 2017 peak volumes; rolling out a completely redesigned front-end; forming integration partnerships with the major liquidity hubs; and launching a research offering. Founded in 2015, B2C2 i

Alnylam Pharmaceuticals and Medison Pharma Partner to Commercialize RNAi Therapeutics in Israel21.1.2019 11:00Tiedote

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma, Israel’s leading commercial partner for innovative pharmaceuticals, announced today an exclusive agreement to commercialize ONPATTRO®, the first-ever commercialized RNAi therapeutic, as well as other investigational therapeutics under development in the Alnylam RNAi portfolio. “Our partnership with Medison marks an important step in our global commercial expansion and signals our intent to ensure that patients suffering from serious rare diseases have access to our medicines, regardless of location,” said Theresa Heggie, SVP and Head of Europe, Middle East and Africa, and Canada, Alnylam Pharmaceuticals. “Medison has a strong organization with a proven track record of commercializing orphan products successfully, together with an infrastructure uniquely suited to supporting patients suffering from rare diseases in Israel and providing access to our potentially transformational thera

Gore Introduces GORE® TAG® Conformable Thoracic Stent Graft with Reduced Profiles in Europe21.1.2019 11:00Tiedote

W. L. Gore & Associates, Inc. (Gore) today introduced reduced profiles for the most commonly used diameters of the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System. The reduced profile allows physicians to perform TEVAR in patients with smaller vessels where access is challenging and aortic anatomy is tortuous, expanding the availability of Gore’s thoracic stent graft to a greater population of patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190121005042/en/ GORE(R) TAG(R) Conformable Thoracic Stent Graft with ACTIVE CONTROL System (Photo: Business Wire) The GORE® TAG® Conformable Thoracic Stent Graft was modified to reduce the delivery profile of the 31, 37, and 40 mm device diameters by 2 Fr for all lengths. The reduction in profile, through the use of a smaller diameter primary sleeve, is the only change to the device. The stent graft leverages the same predictable outcomes of the time-teste

HCL 2030 Ecosystem Platform to Explore Societal Implications of Emerging Technology at the World Economic Forum21.1.2019 10:26Tiedote

HCL Technologies (HCL), a leading global technology company and the World Economic Forum’s Strategic Partner, today announced its largest presence to date at the side-lines of World Economic Forum’s Annual Meeting in Davos scheduled from 21st January 2019 to 25th January 2019. The company will host a three-day event in a special Pavilion that will feature a technology showcase, thought-leadership programs, as well as a number of high-level networking and social events throughout the tenure of the conference. The overarching theme of the HCL and Fast Company programs will explore how humanity’s relationship with technology will evolve through the next decade of rapid innovation. HCL has partnered with Fast Company to develop a thought-leadership track that includes three panel discussion breakfasts. As part of the theme of Human-Machine Harmony, HCL is launching the HCL 2030 Platform, together with its ecosystem of partners and stakeholders, that will conduct in-depth explorations and d

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme